-- Jeffrey Bishop, Ph.D. and Linda M. Greub Join Singulex Leadership Team --
Singulex Announces Key Additions to Executive Management Team
Media:BrewLifeKelly France, 415-946-1076orInvestors:Blueprint Life Science GroupChris Kim, 415-375-3340
Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced the appointment of Jeffrey Bishop, Ph.D. as Vice President, Research and Development and Linda M. Greub as Vice President, Business Development. Dr. Bishop will oversee all R&D efforts, including assay and technology development for clinical diagnostics and life science research, as well as the addition of new content to the clinical laboratory. Ms. Greub is responsible for leading the company’s partnering, licensing and merger & acquisition activities.
“We are thrilled to have Jeff and Linda join the Singulex team,” said Guido Baechler, President and Chief Executive Officer at Singulex. “Jeff has a proven track record in assay and instrument development and will play a critical role in identifying and developing opportunities to expand our product pipeline. Linda brings a wealth of strategic and transactional experience to Singulex and will be a key member of the team as we move to expand the adoption of SMC technology by existing and new partners.”
Dr. Bishop brings extensive diagnostic industry experience to Singulex. He held a variety of leadership positions within the Research and Development organization at Alere, Inc. (formerly Biosite Diagnostics), including recent roles as Vice President, Research and Development for specific platforms and disease areas. While at Alere, Dr. Bishop developed point-of-care assays in the areas of Cardiovascular Disease, Infectious Disease, Women’s Health and Toxicology. Dr. Bishop received his M.S. and Ph.D. degrees in Bioengineering from the University of California, San Diego.
Ms. Greub has over 25 years of business development, strategy, investment and capital-raising experience. She joins Singulex from Novartis Diagnostics where she was Global Director of Strategy, Business Development and M&A. Ms. Greub also served as Senior Director, Strategy and Business Development at Applied Biosystems (Life Technologies) and as a senior healthcare analyst for several investment banks and hedge funds, including Banc of America Securities and Essex Investment Management. Ms. Greub earned a B.A. from Yale University, an M.B.A from the Harvard Business School and is a Chartered Financial Analyst.
Singulex is the developer and leading provider of single molecule counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.
Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC. Singulex currently is developing the Singulex Clinical Diagnostic System, a fully-automated diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit .